CY1835A - Low dose benazepril/thiazide diuretic composition - Google Patents
Low dose benazepril/thiazide diuretic composition Download PDFInfo
- Publication number
- CY1835A CY1835A CY183595A CY183595A CY1835A CY 1835 A CY1835 A CY 1835A CY 183595 A CY183595 A CY 183595A CY 183595 A CY183595 A CY 183595A CY 1835 A CY1835 A CY 1835A
- Authority
- CY
- Cyprus
- Prior art keywords
- composition according
- benazepril
- hydrochlorothiazide
- thiazide diuretic
- dose
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 22
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 title claims description 18
- 229960004530 benazepril Drugs 0.000 title claims description 18
- 239000003451 thiazide diuretic agent Substances 0.000 title claims description 17
- 229940121792 Thiazide diuretic Drugs 0.000 title claims description 14
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 24
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 20
- 229960003619 benazepril hydrochloride Drugs 0.000 claims description 8
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 claims description 8
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 5
- 229960002155 chlorothiazide Drugs 0.000 claims description 4
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 claims description 3
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229960001523 chlortalidone Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003515 bendroflumethiazide Drugs 0.000 claims description 2
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960001541 benzthiazide Drugs 0.000 claims description 2
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003176 cyclothiazide Drugs 0.000 claims description 2
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 claims description 2
- 229960003313 hydroflumethiazide Drugs 0.000 claims description 2
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 claims description 2
- 229960005483 polythiazide Drugs 0.000 claims description 2
- 229920000046 polythiazide Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229960004813 trichlormethiazide Drugs 0.000 claims description 2
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 claims description 2
- 229940100691 oral capsule Drugs 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 239000007935 oral tablet Substances 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000005541 ACE inhibitor Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000011162 core material Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 229940097420 Diuretic Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- -1 with inorganic acid Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30038389A | 1989-01-23 | 1989-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1835A true CY1835A (en) | 1995-12-01 |
Family
ID=23158879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY183595A CY1835A (en) | 1989-01-23 | 1995-12-01 | Low dose benazepril/thiazide diuretic composition |
Country Status (24)
| Country | Link |
|---|---|
| JP (1) | JP3009694B2 (enExample) |
| KR (1) | KR0141479B1 (enExample) |
| AT (1) | AT401728B (enExample) |
| AU (1) | AU629288B2 (enExample) |
| BE (1) | BE1002736A4 (enExample) |
| CA (1) | CA2008126C (enExample) |
| CH (1) | CH680568A5 (enExample) |
| CY (1) | CY1835A (enExample) |
| DE (2) | DE4001496C2 (enExample) |
| DK (1) | DK175204B1 (enExample) |
| FR (1) | FR2641971B1 (enExample) |
| GB (1) | GB2227172B (enExample) |
| HK (1) | HK98995A (enExample) |
| IE (1) | IE61784B1 (enExample) |
| IL (1) | IL93117A0 (enExample) |
| IT (1) | IT1239744B (enExample) |
| LU (1) | LU87660A1 (enExample) |
| MX (1) | MX9203362A (enExample) |
| NL (1) | NL194958C (enExample) |
| NZ (1) | NZ232182A (enExample) |
| SA (1) | SA90100151B1 (enExample) |
| SE (1) | SE506179C2 (enExample) |
| SG (1) | SG176194G (enExample) |
| ZA (1) | ZA90429B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100221695B1 (ko) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
| DK9200258U4 (da) * | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Farmaceutisk præparat indeholdende enalapril til brug mod hypertension |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| CN102579346B (zh) * | 2012-03-02 | 2013-09-25 | 海南美兰史克制药有限公司 | 贝那普利/氢氯噻嗪药物组合物脂质体固体制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217347A (en) * | 1977-12-27 | 1980-08-12 | E. R. Squibb & Sons, Inc. | Method of treating hypertension and medicaments therefor |
| IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| US4410520A (en) * | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
| ZA833903B (en) * | 1982-06-01 | 1984-11-28 | Merck & Co Inc | Benzofused lactams as antihypertensives |
| US4520021A (en) * | 1982-07-02 | 1985-05-28 | Merck & Co., Inc. | Substituted caprolactam derivatives as antihypertensives |
-
1990
- 1990-01-08 SE SE9000050A patent/SE506179C2/sv not_active IP Right Cessation
- 1990-01-15 CH CH112/90A patent/CH680568A5/de not_active IP Right Cessation
- 1990-01-17 GB GB9001054A patent/GB2227172B/en not_active Expired - Lifetime
- 1990-01-18 LU LU87660A patent/LU87660A1/de unknown
- 1990-01-19 CA CA002008126A patent/CA2008126C/en not_active Expired - Lifetime
- 1990-01-19 DE DE4001496A patent/DE4001496C2/de not_active Expired - Lifetime
- 1990-01-19 DE DE2001199041 patent/DE10199041I1/de active Pending
- 1990-01-19 IT IT47548A patent/IT1239744B/it active IP Right Grant
- 1990-01-19 NZ NZ232182A patent/NZ232182A/en unknown
- 1990-01-19 FR FR909000612A patent/FR2641971B1/fr not_active Expired - Lifetime
- 1990-01-22 AT AT0013590A patent/AT401728B/de not_active IP Right Cessation
- 1990-01-22 NL NL9000158A patent/NL194958C/nl not_active IP Right Cessation
- 1990-01-22 KR KR1019900000697A patent/KR0141479B1/ko not_active Expired - Lifetime
- 1990-01-22 DK DK199000174A patent/DK175204B1/da not_active IP Right Cessation
- 1990-01-22 IL IL93117A patent/IL93117A0/xx not_active IP Right Cessation
- 1990-01-22 ZA ZA90429A patent/ZA90429B/xx unknown
- 1990-01-22 JP JP2010782A patent/JP3009694B2/ja not_active Expired - Lifetime
- 1990-01-22 AU AU48703/90A patent/AU629288B2/en not_active Expired
- 1990-01-22 IE IE23390A patent/IE61784B1/en not_active IP Right Cessation
- 1990-01-22 BE BE9000074A patent/BE1002736A4/fr not_active IP Right Cessation
- 1990-04-04 SA SA90100151A patent/SA90100151B1/ar unknown
-
1992
- 1992-06-25 MX MX9203362A patent/MX9203362A/es unknown
-
1994
- 1994-12-16 SG SG176194A patent/SG176194G/en unknown
-
1995
- 1995-06-22 HK HK98995A patent/HK98995A/xx not_active IP Right Cessation
- 1995-12-01 CY CY183595A patent/CY1835A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1212081B2 (en) | Use of ramipril in the prevention of congestive heart failure | |
| US6162802A (en) | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor | |
| US20070105894A1 (en) | Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor | |
| AU712914B2 (en) | Antifungal composition | |
| US4766117A (en) | Antiinflammatory compositions and methods | |
| JPH1036269A (ja) | 月経困難症及び／又は月経前症候群の軽減用薬剤 | |
| US4579846A (en) | Antiinflammatory compositions and methods | |
| US20020183291A1 (en) | Product for treating gynecomastia | |
| CA2008126C (en) | Low dose benazepril/thiazide diuretic composition | |
| EP0190851B1 (en) | Improved antiinflammatory composition | |
| US4874757A (en) | Antinflammatory compositions and methods | |
| WO1994002144A1 (en) | Use of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone in the treatment of angina pectoris | |
| US4812455A (en) | Antiinflammatory compositions and methods | |
| US4672061A (en) | Antiinflammatory compositions and methods | |
| AU615932B2 (en) | Uricosuric composition | |
| IE43955B1 (en) | Pharmaceutical composition and dosage units thereof | |
| IE922558A1 (en) | Medicinal treatment | |
| JPH1081632A (ja) | 医 薬 | |
| NZ199783A (en) | Sustained release compositions containing endralazine embedded in a wax matrix |